Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972035 · ClinicalTrials.gov registry record · Phase 2
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT01972035 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 137 participants.
The verdict
NCT01972035, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant. 2. the side effects of the anti-viral drugs requiring dose reduction or cessation In addition, we will test renal tissue obtained from any biopsies post-transplant (surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and fluorescence in situ hybridization to assess for latent CMV and/or EBV.
Interventions
- DRUG Valacyclovir
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972035
The ClinicalTrials.gov registry entry for NCT01972035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valacyclovir is the first listed.
NCT01972035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01972035 about?
NCT01972035 is a clinical study titled "ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation". Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant. 2. the side effects of the anti-viral drugs req...
What is the current status of trial NCT01972035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2014-08-01. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT01972035?
The interventions under investigation include: Valacyclovir (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT01972035?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.